{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:41:24Z","timestamp":1760960484237,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Gynecologic carcinosarcomas (GCSs) are rare cancers with poor prognoses. In this study, we aimed to analyze the chemotherapy regimens used to treat GCSs at our institution, as well as the patients\u2019 outcomes. Methods: We conducted a retrospective analysis of 62 GCS patients treated at Hospital Clinico san Carlos (HCSC) from 1995 to 2024. Results: Data from 62 GCSs were analyzed. Fifty-two patients (84%) underwent surgery at diagnosis, followed by radiotherapy in 20 (38.5%) endometrial carcinosarcoma (ECS) patients and perioperative chemotherapy in 45 GCS patients (62.6%). After a median follow-up (mFollow-up) of 20 months (0\u2013242 months), 23 GCS patients relapsed and 13 progressed after the first treatment approach, 3 of them almost immediately after surgery. The median time to disease relapse was 6 months (0\u2013225 months) and the median time to disease progression was 0 months (0\u201325 months). Sixteen of the relapsing patients and fifteen of the patients who were diagnosed at stage IV received systemic treatment with carboplatin and paclitaxel, the most common forms of chemotherapy (used as first-line treatments in eight of the relapsing patients and in seven patients who were in stage IV at diagnosis). GCS patients received up to five lines. The median progression-free survival (mPFS) was 5 months for the first line, and decreased in the following lines. The median overall survival (mOS) was 24 months (13.5\u201334.5 months) and 11 months (1\u2013226 months) after GCS relapse\/progression. Conclusions: GCS is a rare and aggressive disease with a high recurrence rate after surgery and short progression-free survival (PFS) at advanced stages, even when a combination of oncological therapies are used. (Nevertheless, some patients achieved long disease-free survival). To the best of our knowledge, this is the first publication to provide this valuable data on this rare and aggressive disease, for which phase III and real-world data is scarce.<\/jats:p>","DOI":"10.3390\/cancers17203359","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T16:13:03Z","timestamp":1760717583000},"page":"3359","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy and Other Systemic Drugs Used to Treat Gynecologic Carcinosarcomas (GCSs): A Retrospective Analysis from Hospital Cl\u00ednico San Carlos (HCSC), An Academic Referral Centre for Rare Gynecological Malignancies in Madrid, Spain"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-9787","authenticated-orcid":false,"given":"Gloria","family":"Marquina","sequence":"first","affiliation":[{"name":"School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6560-1621","authenticated-orcid":false,"given":"Beatriz","family":"Gonzalez-Diez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Clinico San Carlos, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-2015","authenticated-orcid":false,"given":"Pluvio J.","family":"Coronado","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier Garcia","family":"Santos","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bellon","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3462-4183","authenticated-orcid":false,"given":"Rafael Sanchez","family":"del Hoyo","sequence":"additional","affiliation":[{"name":"Research Methodological Support Unit and Preventive Department, Hospital Clinico San Carlos, IdISSC, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Pascual","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6100-4967","authenticated-orcid":false,"given":"Cristina Diaz","family":"del Arco","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8110-3145","authenticated-orcid":false,"given":"Noelia Sanmamed","family":"Salgado","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Cerezo","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1291-4160","authenticated-orcid":false,"given":"Ramiro","family":"Mendez","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Manuel","family":"Espejo","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8342-2414","authenticated-orcid":false,"given":"Angel","family":"Nava","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7589-5695","authenticated-orcid":false,"given":"Susana","family":"Martin Garre","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Ortega","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Hospital Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Casado","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Complutense de Madrid, IdISSC, EURACAN Referral Center, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/IGC.0000000000000296","article-title":"Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma","volume":"24","author":"Ledermann","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.3802\/jgo.2018.29.e22","article-title":"Trends of uterine carcinosarcoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2013.07.097","article-title":"Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: A SEER analysis","volume":"131","author":"Diver","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/IGC.0b013e3181dc8292","article-title":"Ovarian and uterine carcinosarcomas: A comparative analysis of prognostic variables and survival outcomes","volume":"20","author":"Garg","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: Pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.bulcan.2023.07.005","article-title":"Gynecological carcinosarcomas: Overview and future perspectives","volume":"110","author":"Collet","year":"2023","journal-title":"Bull. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"FIGO Committee on Gynecologic Oncology, Staging classification for cancer of the ovary, fallopian tube, and perito-neum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/IGC.0000000000000215","article-title":"Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: A retrospective cohort study","volume":"24","author":"Lorusso","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/IGC.0000000000000302","article-title":"Paclitaxel and Carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: A phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit","volume":"25","author":"Otsuki","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ygyno.2004.11.022","article-title":"Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: A Gynecologic Oncology Group study","volume":"96","author":"Sutton","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2007.08.084","article-title":"Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience","volume":"108","author":"Hoskins","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"E269","DOI":"10.1016\/j.ijrobp.2015.07.1225","article-title":"The Impact of Adjuvant Therapy on Survival Endpoints in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study","volume":"93","author":"Guttmann","year":"2015","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ygyno.2009.10.053","article-title":"The impact of multi-modal therapy on survival for uterine carcinosarcomas","volume":"116","author":"Terstriep","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/s-0042-100205","article-title":"Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Carcinosarcoma: A Retrospective Case Series","volume":"76","author":"Wallwiener","year":"2016","journal-title":"Geburtshilfe Und Frauenheilkd."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0959-8049(02)00740-2","article-title":"Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923)","volume":"39","author":"Vermorken","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1200\/JCO.2009.26.8326","article-title":"Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group study","volume":"28","author":"Powell","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.21.02050","article-title":"Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial","volume":"40","author":"Powell","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin\u2013paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0090-8258(03)00332-9","article-title":"A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uter-ine malignant mixed m\u00fcllerian tumors with evaluation of potential molecular targets","volume":"90","author":"Ramondetta","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.2000.6001","article-title":"A Phase III Trial of Ifosfamide with or without Cisplatin in Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study","volume":"79","author":"Sutton","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ygyno.2010.03.024","article-title":"A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: A gynecologic oncology group study","volume":"118","author":"Miller","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0971-5851.92814","article-title":"Uterine carcinosarcomas: 8-year single center experience of 25 cases","volume":"32","author":"Dave","year":"2011","journal-title":"Indian J. Med Paediatr. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13193-012-0206-7","article-title":"Carcinosarcoma of the Uterus\u2014A Single Institution Retrospective Analysis of the Management and Outcome and a Brief Review of Literature","volume":"4","author":"Anupama","year":"2013","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7607","DOI":"10.3390\/curroncol29100601","article-title":"Management and Prognosis of Patients with Recurrent or Persistent\/Progressive Uterine Carcinosar-coma","volume":"29","author":"Tung","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Terblanche, L., and Botha, M.H. (2022). Uterine carcinosarcoma: A 10-year single institution experience. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0271526"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3359\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:58:13Z","timestamp":1760957893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":30,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17203359"],"URL":"https:\/\/doi.org\/10.3390\/cancers17203359","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}